New Specialist Therapies
Innovative responses to unmet needs
In addition to strengthening our core therapeutic areas, Merck Serono’s strategy is to expand its product offerings into new specialist areas with significant unmet medical needs. Combining our own R&D pipeline compounds with key partnering opportunities is a key component of our approach.
Merck Serono conducts research in the area of autoimmune and inflammatory diseases (AIID) in order to offer new therapeutic options to patients with high unmet medical needs. We currently have several innovative projects in our R&D pipeline that may soon provide new therapies for diseases such as systemic lupus erythematosus and rheumatoid arthritis.
| Disclaimer |
This section gives an overview of our Company's activities in specialist therapies. The information may refer to pharmaceutical products, therapeutics or indications not yet registered or approved in a given country. US Residents should consult the EMD Serono, Inc. for information on products approved for sale in the United States of America. |
